Similar articles for PMID: 28197239

Year	Number of Results
2012	11
2013	7
2014	16
2015	14
2016	17
2017	16
2018	14
2019	8
2020	3
2022	2
2023	3
2024	2

1

Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban.

Eikelboom JW, Connolly SJ. Eikelboom JW, et al. Cardiol Res. 2015 Jun;6(3):267-277. doi: 10.14740/cr413w. Epub 2015 Jun 11. Cardiol Res. 2015. PMID: 28197239 Free PMC article. Review.

2

Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.

Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, Lo-Ciganic WH. Almutairi AR, et al. Clin Ther. 2017 Jul;39(7):1456-1478.e36. doi: 10.1016/j.clinthera.2017.05.358. Epub 2017 Jun 28. Clin Ther. 2017. PMID: 28668628 Review.

3

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.

Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB. Nielsen PB, et al. BMJ. 2017 Feb 10;356:j510. doi: 10.1136/bmj.j510. BMJ. 2017. PMID: 28188243 Free PMC article.

4

Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.

Zheng Y, Sorensen SV, Gonschior AK, Noack H, Heinrich-Nols J, Sunderland T, Kansal AR. Zheng Y, et al. Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23. Clin Ther. 2014. PMID: 25438722 Free article.

5

Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.

Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A, Tushabe D, Batson S. Cohen AT, et al. PLoS One. 2015 Dec 30;10(12):e0144856. doi: 10.1371/journal.pone.0144856. eCollection 2015. PLoS One. 2015. PMID: 26716830 Free PMC article. Review.

6

Long-term benefits of preventing venous thromboembolic events.

Cohen AT. Cohen AT. Curr Med Res Opin. 2012 Jun;28(6):877-89. doi: 10.1185/03007995.2012.688737. Epub 2012 May 24. Curr Med Res Opin. 2012. PMID: 22533680 Review.

7

Expanding use of new oral anticoagulants.

Weitz JI. Weitz JI. F1000Prime Rep. 2014 Oct 1;6:93. doi: 10.12703/P6-93. eCollection 2014. F1000Prime Rep. 2014. PMID: 25374671 Free PMC article. Review.

8

Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.

Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, Batson S. Lip GY, et al. Int J Cardiol. 2016 Feb 1;204:88-94. doi: 10.1016/j.ijcard.2015.11.084. Epub 2015 Nov 17. Int J Cardiol. 2016. PMID: 26655548

9

Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P. Lip GY, et al. Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6. Clin Ther. 2014. PMID: 24508420 Free article.

10

Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.

Jugrin AV, Hösel V, Ustyugova A, De Francesco M, Lamotte M, Sunderland T. Jugrin AV, et al. J Med Econ. 2016;19(1):1-10. doi: 10.3111/13696998.2015.1078340. Epub 2015 Sep 21. J Med Econ. 2016. PMID: 26390231 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

94 results

Results by year